Introduction
============

As the world\'s ageing population increases, ST-segment elevation myocardial infarction (STEMI) incidence is expected to increase to be the most common and fatal cardiac emergency ([@b1-etm-0-0-8626]). Acute myocardial infarction (AMI) is often caused by the interruption of coronary artery blood flow and myocardial ischemic necrosis resulting from decreased stability of coronary atherosclerotic plaque, ulcer, rupture and other thrombosis ([@b2-etm-0-0-8626]). Therefore, early, rapid and complete opening of the infarcted artery is key to improving the prognosis of patients with STEMI ([@b2-etm-0-0-8626],[@b3-etm-0-0-8626]). Percutaneous coronary intervention (PCI) is a non-surgical method used in extensive myocardial reperfusion therapy ([@b4-etm-0-0-8626]). Early risk stratification and identification of high-risk patients with STEMI are of great significance in prognosis, and also in guiding diagnosis and treatment decisions ([@b5-etm-0-0-8626]). Currently, the Global Registry of Acute Coronary Events (GRACE) score is widely used as an acute risk stratification tool in the evaluation of prognosis in patients with acute coronary syndrome (ACS) ([@b6-etm-0-0-8626]). GRACE score parameters include age, systolic blood pressure, pulse, serum creatinine, Killip classification at admission, cardiac arrest at admission, markers of myocardial necrosis and changes in ST-segment ([@b7-etm-0-0-8626]). These eight independent risk factors of prognosis are not only a predictive value for risk stratification and nosocomial adverse outcomes in patients with ACS, but also has a significant predictive power in both short- and long-term major adverse cardiovascular events (MACE), including all-cause mortality ([@b8-etm-0-0-8626]). Jakimov *et al* ([@b9-etm-0-0-8626]) showed that the GRACE score at admission is an independent predictor of MACE over a 30-day follow-up period. Xiang *et al* ([@b10-etm-0-0-8626]) showed that the GRACE score at admission was an independent predictor of long-term MACE in patients with AMI. The GRACE score is a comprehensive assessment system guiding clinical diagnosis, treatment and prognosis evaluation. However, there are some limitations, including a lack of biomarkers that reflect thrombosis and inflammation ([@b11-etm-0-0-8626],[@b12-etm-0-0-8626]).

Previous findings have shown that thrombosis and inflammation play central roles in the occurrence, progression, rupture and thrombosis of atherosclerotic plaques ([@b13-etm-0-0-8626]). Platelets form an important link between inflammatory reactions and thrombosis ([@b14-etm-0-0-8626]). At admission, large platelets actively participate in metabolism and enzyme activity compared with smaller platelets, which have greater thrombosis potential ([@b14-etm-0-0-8626]). The mean platelet volume (MPV) is easy to measure, is a stable parameter of platelet activation and aggregation, and plays an important role in predicting the adverse outcomes in patients with STEMI ([@b15-etm-0-0-8626],[@b16-etm-0-0-8626]). Lymphocytes are one of the earliest cell types involved in atherosclerotic plaque formation and are important biomarkers in determining the inflammatory state of the body ([@b17-etm-0-0-8626]). Lymphocytes have multiple functions, including producing immunoglobulin M antibodies, recognizing and oxidizing low-density lipoprotein, and preventing atherosclerosis ([@b17-etm-0-0-8626],[@b18-etm-0-0-8626]). Therefore, in the present study, the mean platelet volume to lymphocyte ratio (MPVLR) was used as a new potential biomarker for inflammation and thrombosis. Recent studies have reported that high MPVLR values at admission are associated with various short-term and long-term adverse outcomes in patients with STEMI after PCI ([@b19-etm-0-0-8626],[@b20-etm-0-0-8626]). However, there are no previous studies evaluating the association between MPVLR and GRACE score, and the combined value of MPVLR with GRACE score in predicting the prognosis of patients with STEMI after PCI. Therefore, aims of the present study were to assess the potential association between MPVLR and GRACE score, and to investigate whether combined MPVLR and GRACE score is a powerful predictor of short-term MACE in patients with STEMI after PCI.

Materials and methods
=====================

### Study population

This study was retrospective and conducted at the First Affiliated Hospital of Shihezi University Medical College from October 2017 to January 2019, enrolling 556 patients (including 321 males and 235 females, aged between 20 and 90 years) diagnosed with STEMI who underwent primary PCI within 12 h. The study was approved by The Ethics Committee of The First Affiliated Hospital of Shihezi University School of Medicine.

STEMI was diagnosed based on the American College of Cardiology ([@b21-etm-0-0-8626]) and included the following criteria: i) Chest pain symptoms occurring within 24 h prior to admission and lasting for \>30 min; ii) an electrocardiogram showing ST-segment elevation in ≥2 consecutive leads and/or an abnormal Q wave and new left bundle-branch block; and iii) serum biochemical marker creatinine kinase-myocardial band isoenzyme (CK-MB) and/or cardiac troponin T (cTnT) is positively elevated within 24 h after onset of the symptoms. The following patients were excluded to avoid any factors that could have affected MPVLR: i) Patients with autoimmune diseases (n=8); ii) congenital heart diseases (n=4); iii) cancer (n=17); iv) acute and chronic infectious diseases (n=13); v) severe liver and kidney dysfunction diseases (n=19); vi) those taking steroid drugs within 3 months (n=10): vii) those who previously underwent PCI (n=13); viii) patients with incomplete clinical data (n=5); ix) medication is not regularly taken; and x) poor compliance. Out of 556 patients initially enrolled, 464 patients met the inclusion criteria, and all provided written informed consent. 'Prodromal angina' (PA) was defined as a chest pain episode typically limited to 24 h before infarction ([@b22-etm-0-0-8626]). No-reflow was defined as the absence of effective perfusion of myocardial tissue (TIMI flow-grade lower than 3) after coronary artery recanalization without obvious spasm, dissection and residual stenosis ([@b23-etm-0-0-8626]).

### Study procedures and clinical data

Peripheral venous blood samples (4 ml) were collected from patients prior to PCI. Hematological and biochemical analyses were performed using fresh whole blood and plasma within 30 min of collection. The hematological parameters included testing for the neutrophil count, lymphocyte count, highly sensitive c-reactive protein (hsCRP) and MPV, which were measured using an XT-4000 automated hematology analyzer (Sysmex Corporation). The biochemical indicators analyzed included blood glucose, cTnT, CK-MB and N-terminal pro-brain natriuretic peptide (NT-proBNP). CK-MB, cTnT and NT-proBNP were determined using a Roche E601 immunology analyzer (Roche Diagnostics), while blood glucose was measured using an Hitachi7180 automatic biochemical analyzer (Hitachi, Ltd.). MPVLR was calculated based on the ratio of mean platelet volume to lymphocyte count at admission ([@b20-etm-0-0-8626]). Using a computer program on the national chest pain center platform (<https://datacs.chinacpc.org>), the first attending physician recorded the GRACE scores of all the patients at admission. All the patients underwent Philips iE33 transthoracic echocardiography (Philips Healthcare) to assess left ventricular ejection fraction (LVEF) within 24 h after PCI.

Prior to PCI, all the patients received 300 mg clopidogrel (Sanofi S.A.), 300 mg aspirin (Bayer), and after PCI received daily doses of 75 mg clopidogrel and 100 mg aspirin. The use and dosage of other cardiac drugs were determined by the clinician according to the clinical guidelines formulated by the American College of Cardiology and the condition of the patient ([@b21-etm-0-0-8626]). The success of PCI was assessed via thrombolysis in myocardial infarction flow grade level 3 after coronary artery therapy and residual stenosis of \<30% ([@b20-etm-0-0-8626]). Coronary angiography, PCI and reperfusion therapy strategies were performed by experienced cardiologists.

### Primary endpoint and follow-up

Follow up of patients was completed by reviewing hospital records, outpatient visits and telephone contact. The main outcome was that MACE occurred during the follow-up period. MACE included: Cardiogenic or all-cause mortality, malignant arrhythmias (ventricular tachycardia, ventricular fibrillation, grade III atrioventricular block), recurrent myocardial infarction, recurrent angina, acute heart failure and stroke (neurological disorders related to recent ischemic or hemorrhagic events) ([@b24-etm-0-0-8626]).

### Statistical analysis

The Kolmogorov-Smirnov test was used to determine the normality of each of the random samples. Mean and standard deviation were used to describe the numerical variables following a normal distribution. However, the median and interquartile range were used to describe numerical variables not following normal distribution. The t-test or Mann-Whitney U test were used to compare the numerical variables between two groups, while one-way ANOVA was used to compare the numerical variables among multiple groups. When differences between the two groups were needed to be compared using ANOVA, Tukey\'s post-hoc test was used if equal variances were assumed, and Games-Howell post-hoc test was used if equal variances were not assumed. Non-normally distributed data were analyzed with the Kruskal-Wallis non-parametric test, followed by Dunn\'s post-hoc test. Frequencies and percentages were used to describe nominal variables, and comparisons between groups performed using χ^2^ test or Fisher exact probability method. Spearman\'s rank correlation was utilized to determine the correlation between MPVLR and GRACE scores. A receiver operating characteristic curve (ROC) was used to analyze the value of MPVLR, GRACE score and their combination in predicting MACE and angiographic no-reflow occurrence. Delong\'s test was used to compare the area under ROC curve (AUC). Kaplan-Meier analysis method was used to estimate the MACE-free survival rate based on the cut-off values of MPVLR and GRACE scores. The log-rank test was used to compare the MACE free survival rate between groups. Cox regression models were used to evaluate independent risk factors for short-term MACE in patients with STEMI after PCI. Univariate analysis P\<0.1 factors were included in multivariate Cox regression analysis. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Baseline clinical characteristics

The present study enrolled 464 patients with STEMI after PCI and the median follow-up period was 22 days (range: 1-30). [Fig. 1](#f1-etm-0-0-8626){ref-type="fig"} shows the patient selection flow chart. ROC analyses results indicated that the cut-off values of MPVLR and GRACE score for differentiating short-term MACE were 5.38 (sensitivity=85.2%; specificity=64.6%; P\<0.001) and 145 (sensitivity=88.9%; specificity=62.7%; P=0.005). Based on the optimal cut-off values of MPVLR and GRACE score, patients were segregated into four groups ([@b25-etm-0-0-8626]): i) Low MPVLR + low GRACE score (Group 1; MPVLR ≤5.38; GRACE score ≤145; n=181); ii) low MPVLR + high GRACE score (Group 2; MPVLR ≤5.38; GRACE score \>145; n=91); iii) high MPVLR + low GRACE score (Group 3; MPVLR \>5.38; GRACE score ≤145; n=93); and iv) high MPVLR + high GRACE score (Group 4; MPVLR \>5.38; GRACE score \>145; n=99). The basic clinical and procedural characteristics of the four groups of patients are shown in [Table I](#tI-etm-0-0-8626){ref-type="table"}. Patients in Group 4 were significantly older, had a higher admission GRACE score, Killip class, neutrophil count, neutrophil to lymphocyte ratio (NLR), MPV, MPVLR, peak of cTnT, NT-proBNP and hsCRP, and lower levels of LVEF and lymphocyte count compared to patients in Group 1. Patients in Group 4 also had a higher proportion of diabetes mellitus and PA compared with the other three groups. Moreover, there were no significant differences in coronary angiography and postoperative medication among the four groups.

### Comparison of baseline clinical characteristics of patients in the MACE and MACE-free groups

[Table II](#tII-etm-0-0-8626){ref-type="table"} shows the baseline clinical characteristics of patients in the MACE and MACE-free groups. Compared to the MACE-free group, the MACE group patients were older, had higher neutrophil count, NLR, MPV, peak of cTnT, NT-proBNP, hsCRP, and also a higher proportion of diabetes and killip class≥II. However, patients with MACE had a lower proportion of PA, lymphocyte count and LVEF. Moreover, the MPVLR and GRACE score of patients in the MACE group were significantly higher compared with the MACE-free group.

### Clinical adverse outcomes

During the follow-up period, 54 (11.64%) patients experienced MACE. These included 22 (4.74%) cardiac or all-cause mortality, seven (1.51%) malignant arrhythmia, 11 (2.37%) recurrent angina, four (0.86%) recurrent myocardial infarction, eight (1.72%) acute heart failure and two (0.43%) strokes. The present results suggested that the incidence of MACE and angiographic no-reflow during follow-up were significantly increased in the high MPVLR + high GRACE score group compared with the other three groups. In terms of cardiac or all-cause mortality and recurrent angina, these were significantly increased in patients in the high MPVLR + high GRACE score group compared with the other three groups. However, malignant arrhythmia, recurrent angina, acute heart failure and stroke were similar in the four groups ([Table III](#tIII-etm-0-0-8626){ref-type="table"}).

Kaplan-Meier survival curves based on the cut-off values of MPVLR and GRACE score are shown in [Fig. 2A](#f2-etm-0-0-8626){ref-type="fig"} and [B](#f2-etm-0-0-8626){ref-type="fig"}, respectively. The rate of MACE in the high MPVLR group (19.79 vs. 5.88%; log-rank, P\<0.001; [Fig. 2A](#f2-etm-0-0-8626){ref-type="fig"}) and the high GRACE score group (18.42 vs. 6.93%; log-rank, P\<0.001; [Fig. 2B](#f2-etm-0-0-8626){ref-type="fig"}) increased significantly compared with the control group during the follow-up period. In addition, Kaplan-Meier survival curves based on the combined biomarkers (MPVLR and GRACE scores) are shown in [Fig. 2C](#f2-etm-0-0-8626){ref-type="fig"}. There was a significant intergroup difference in short-term MACE among the four groups, and the short-term MACE in the high MPVLR+ high GRACE score group was increased compared with the other three groups (high MPVLR + high GRACE score vs. high MPVLR + low GRACE score vs. low MPVLR + high GRACE score; 25.25 vs. 13.98 vs. 11.00%, respectively; P\<0.001; [Fig. 2C](#f2-etm-0-0-8626){ref-type="fig"}).

### Independent predictors factors for short-term MACE

Cox proportional hazard analysis was used to construct model 1 and model 2 for prediction of the risk factors for short-term MACE after PCI in patients with STEMI ([Table IV](#tIV-etm-0-0-8626){ref-type="table"}). Univariate analysis results suggested that age, prodromal angina, Killip class ≥II, NLR, hsCRP, NT-proBNP, the peak of cTnT, LVEF and combined MPVLR with GRACE score were all associated with a 30-day MACE. After adjusting the covariates in model 1, high GRACE score (HR, 1.706; 95% CI, 1.435-3.058; P\<0.001) and high MPVLR (HR, 1.668; 95% CI, 1.202-2.170; P\<0.001) were significant independent predictors of a 30-day MACE. Multivariate Cox analysis in model 2 showed that the combination of high GRACE score with high MPVLR (HR, 2.455; 95% CI, 1.736-3.188; P\<0.001) was a powerful predictor of a 30-day MACE.

### Correlation between MPVLR and GRACE score

Based on the GRACE score, patients were categorized into three groups: High-risk group (GRACE score \>140; n=213), medium-risk group (108\< GRACE score ≤140; n=161) and low-risk group (GRACE score ≤108; n=90). It was demonstrated that, with increased GRACE risk stratification, the MPVLR level of each group increased significantly (P\<0.05; [Fig. 3](#f3-etm-0-0-8626){ref-type="fig"}). In addition, Spearman\'s rank correlation results indicated that there was a significant linear correlation between MPVLR with GRACE score (ρ=0.304; P\<0.001; [Fig. 4](#f4-etm-0-0-8626){ref-type="fig"}).

### Combination of MPVLR with GRACE score in predicting clinical adverse outcomes

ROC curves assessed and compared the predictive efficacy of MPVLR, GRACE score and their combination in predicting adverse clinical outcomes after PCI in patients with STEMI. As presented in [Fig. 5A](#f5-etm-0-0-8626){ref-type="fig"}, a combination of GRACE score with MPVLR (AUC, 0.853; 95% CI, 0.800-0.907) had improved predictive efficacy for short-term MACE, compared with individual MPVLR (AUC, 0.787; 95% CI, 0.741-0.834) and GRACE score (AUC, 0.808; 95% CI, 0.747-0.869; P\<0.05). In addition, GRACE score together with MPVLR (AUC, 0.776; 95% CI, 0.722-0.831) significantly improved the prediction efficiency of angiographic no-reflow ([Fig. 5B](#f5-etm-0-0-8626){ref-type="fig"}; P\<0.05) compared with single prediction with MPVLR (AUC, 0.650; 95% CI, 0.569-0.732) and GRACE score (AUC, 0.693; 95% CI, 0.628-0.758). Collectively, the present results suggested that the combination of MPVLR and GRACE score may improve the prediction of clinical adverse outcomes in patients with STEMI after PCI.

Discussion
==========

The present study, not only investigated the potential association between GRACE score and MPVLR, but also compared the predictive value of GRACE score, MPVLR and GRACE score combined with MPVLR for no-reflow and short-term MACE in patients with STEMI after PCI. In addition, the present study also examined the potential mechanism between the loss of PA and the increase in MPVLR and GRACE scores. The present results suggested that MPVLR is a simple, non-invasive, economical and feasible biomarker, which can account for the deficiency of the GRACE score system. It was also indicated that MPVLR has a practical clinical value in predicting the prognosis of patients with STEMI. The present findings demonstrated that MPVLR combined with GRACE score has a more powerful predictive potential for short-term adverse outcomes in patients with STEMI after PCI, compared with an individual MPLVR or GRACE score.

MPV is an important indicator of platelet activation and aggregation ([@b26-etm-0-0-8626]). Large platelets with more active metabolism can accelerate the formation of coronary thrombosis, and play a considerable role in the pathological and physiological process of AMI ([@b27-etm-0-0-8626]). Previous clinical studies have shown that higher MPV at the time of admission is associated with all-cause mortality and MACE incidence in patients with STEMI ([@b30-etm-0-0-8626],[@b31-etm-0-0-8626]). Goncalves *et al* ([@b32-etm-0-0-8626]) showed that patients with ACS have larger MPV and larger platelet metabolism and enzyme activities were higher, which increased the occurrence of adverse outcomes via the release of inflammatory mediators, increased thrombosis, aggravated microvascular dysfunction, inflammation and myocardial injury, microcirculation insufficiency, large infarction area and deterioration of cardiac function. Moreover, Núñez *et al* found that lymphocytes are involved in the growth, development, rupture and thrombosis of atherosclerotic plaques ([@b33-etm-0-0-8626]). The decrease in lymphocyte count is related to the body\'s physiological stress, increased inflammatory response and increased apoptosis ([@b33-etm-0-0-8626]). In addition, lymphocyte count was found to be important biomarkers of inflammatory reactions in patients with STEMI, and is associated with MACE and angiographic no-reflow ([@b34-etm-0-0-8626]). The present results suggested that patients in the MACE group had a lower lymphocyte count compared with the MACE-free group. Moreover, patients in the high MPVLR and high GRACE score group showed significantly lower rates of prodromal angina compared with the other three groups. These results are consistent with previous results from Gok *et al* ([@b35-etm-0-0-8626]). However, the relationship between PA absence and increases in MPVLR and GRACE scores is not fully understood. PA may be a process of ischemic preconditioning, which can delay the death of myocardial cells and has a protective effect on the myocardia ischemic injured before reperfusion ([@b22-etm-0-0-8626],[@b36-etm-0-0-8626]). PA not only reduces myocardial infarct size but also protects microcirculation after reperfusion ([@b35-etm-0-0-8626],[@b37-etm-0-0-8626]). Therefore, the absence of PA in patients with STEMI often indicates that the disease is more serious, and the corresponding GRACE score is higher and with poorer prognosis ([@b38-etm-0-0-8626]). In addition, inflammation plays an important role in myocardial ischemia-reperfusion injury ([@b38-etm-0-0-8626]). Therefore, the reason for the higher MPVLR in patients with STEMI in the absence of PA may be associated with the anti-inflammatory effect and inhibition of platelet activation of PA ([@b39-etm-0-0-8626]).

MPVLR is the ratio of MPV to lymphocyte count, and an increase in MPV and/or a decrease in lymphocyte count can result in increased MPVLR ([@b20-etm-0-0-8626]). MPVLR is a comprehensive biomarker for thrombosis and inflammation ([@b29-etm-0-0-8626]). MPVLR combines the advantages of MPV and lymphocytes in indicating the physiological stress in STEMI patients, overcome the shortcomings of each one of them ([@b20-etm-0-0-8626]). In addition, MPVLR functions as an indicator of the body\'s inflammatory response and the degree of thrombosis ([@b19-etm-0-0-8626]). Ornek and Kurtul ([@b40-etm-0-0-8626]) showed that MPVLR predicted impaired coronary collateral circulation in patients with stable coronary artery disease. Moreover, Kilic and Kurtul ([@b41-etm-0-0-8626]) showed that elevated MPVLR is associated with the complexity and severity of coronary atherosclerosis in patients with ACS. The present results indicated that MPVLR levels were positively correlated with GRACE score and that patients in the high MPVLR group had a higher incidence of MACE. Therefore, MPVLR may be used as an auxiliary indicator to predict adverse outcome in patients with STEMI.

The GRACE score is the largest and best-known database prospective study used for ACS ([@b42-etm-0-0-8626]). Patients were enrolled from 30 countries across North and South America, Australia, New Zealand, Asia and Europe, and it has been widely used to identify high-risk patients with AMI and assess prognosis ([@b43-etm-0-0-8626]). The GRACE score system, however, has some limitations, such as it does not consider the thrombotic activity and inflammatory status of the body ([@b44-etm-0-0-8626]). Hence, there is a lack of biomarkers related to adverse outcomes. Thus, there is a need for objective biomarkers for the comprehensive evaluation of prognosis in AMI patients. Previous studies have identified several biomarkers outside the scoring system, such as NT-proBNP ([@b45-etm-0-0-8626]), hsCRP ([@b46-etm-0-0-8626]), neutrophil count ([@b44-etm-0-0-8626]), homocysteine and the fibrinogen-albumin ratio ([@b47-etm-0-0-8626],[@b48-etm-0-0-8626]); these have significantly improved the predictive efficacy of GRACE risk score system for adverse outcomes in patients with ACS. The present study investigated the association between MPVLR and GRACE score, and found that MPVLR combined with GRACE score may be used as a powerful and stable predictor for short-term MACE prediction after PCI in patients with STEMI.

The present study had some limitations. First, the present study was a single-center retrospective study with limited sample size and possible selection bias. Moreover, the prognostic value of other biomarkers for patients with STEMI were not investigated. In addition, the changes in MPVLR were not dynamically observed and there was no assessment of whether a similar predictive value was present in MPVLR after treatment.

In conclusion, MPVLR and GRACE score combination on admission showed significant predictive value for short-term MACE after PCI in patients with STEMI. Therefore, this combination may be used to identify high-risk patients with poor prognosis and aid treatment in the early disease stage. The combination of MPVLR, which is a non-invasive, simple, economical and feasible biomarker, and GRACE score provides a new perspective for the assessment, treatment and prognosis of patients with STEMI.
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![Flow chart of the study cohort. The flow chart presents the selection criteria, exclusion criteria and clinical layout of the study population (MACE group and MACE-free group). MACE, major adverse cardiovascular events.](etm-19-06-3664-g00){#f1-etm-0-0-8626}

![Kaplan-Meier survival curves of 30-day MACE in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention according to the cut-off value of (A) MPVLR and (B) GRACE scores, and (C) according to the combination of MPVLR and GRACE scores. MACE, major adverse cardiovascular events; MPVLR, mean platelet volume to lymphocyte ratio; GRACE, global registry of acute coronary events.](etm-19-06-3664-g01){#f2-etm-0-0-8626}

![Comparison of MPVLR levels in each risk stratification of global registry of acute coronary events score. MPVLR, mean platelet volume to lymphocyte ratio. ^\*^P\<0.05 vs. low risk group; ^&^P\<0.05 vs. medium risk group.](etm-19-06-3664-g02){#f3-etm-0-0-8626}

![A scatter plot showing the correlation between MPVLR and GRACE score. ρ, spearman\'s rank correlation coefficient. MPVLR, mean platelet volume to lymphocyte ratio; GRACE, global registry of acute coronary events.](etm-19-06-3664-g03){#f4-etm-0-0-8626}

![Receiver operating characteristic curves presenting AUC values for MPVLR in combination with GRACE score (MPVLR + GRACE), MPVLR alone and GRACE alone. (A) Short-term MACE and (B) angiographic no-reflow were predicted in patients with STEMI. GRACE, global registry of acute coronary events; MPVLR, mean platelet volume to lymphocyte ratio; MACE, major adverse cardiovascular events; AUC, area under the curve.](etm-19-06-3664-g04){#f5-etm-0-0-8626}

###### 

Comparison of baseline clinical characteristics of patients divided into groups based on the different MPVLR combined with GRACE scores.

  Variable                               Low MPVLR + low GRACE score (Group 1, n=181)   Low MPVLR + high GRACE score (Group 2, n=91)                      Low MPVLR + high GRACE score (Group 3, n=93)                                                              High MPVLR + high GRACE score (Group 4, n=99)                                                                 P-value
  -------------------------------------- ---------------------------------------------- ----------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ---------
  Baseline characteristics                                                                                                                                                                                                                                                                                                                                                         
       Age, years                        53.68±7.91                                     55.43±8.26                                                        53.06±8.94                                                                                                59.42±9.99^[a-c](#tfn1-etm-0-0-8626 tfn2-etm-0-0-8626 tfn3-etm-0-0-8626){ref-type="table-fn"}^                \<0.001
       Male, n (%)                       105 (58.01)                                    55 (60.44)                                                        51 (54.84)                                                                                                57 (57.58)                                                                                                    0.897
       Current smokers, n (%)            94 (51.93)                                     52 (57.14)                                                        41 (44.09)                                                                                                53 (53.54)                                                                                                    0.337
       Hypertension, n (%)               121 (66.85)                                    63 (69.23)                                                        65 (69.89)                                                                                                81 (81.82)                                                                                                    0.062
       Diabetes mellitus, n (%)          49 (27.07)                                     27 (29.67)                                                        35 (37.63)^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"},[b](#tfn2-etm-0-0-8626){ref-type="table-fn"}^     45 (45.45)^[a-c](#tfn1-etm-0-0-8626 tfn2-etm-0-0-8626 tfn3-etm-0-0-8626){ref-type="table-fn"}^                0.012
       Dyslipidaemia, n (%)              52 (28.73)                                     15 (16.48)                                                        23 (24.73)                                                                                                32 (32.32)                                                                                                    0.179
       Prodromal angina, n (%)           60 (33.15)                                     28 (30.77)                                                        30 (32.26)                                                                                                17 (17.17^[a-c](#tfn1-etm-0-0-8626 tfn2-etm-0-0-8626 tfn3-etm-0-0-8626){ref-type="table-fn"}^                 0.032
       Killip class ≥II, n (%)           66 (36.46)                                     35 (38.46)                                                        40 (43.01)^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"},[b](#tfn2-etm-0-0-8626){ref-type="table-fn"}^     55 (55.56)^[a-c](#tfn1-etm-0-0-8626 tfn2-etm-0-0-8626 tfn3-etm-0-0-8626){ref-type="table-fn"}^                0.017
       GRACE score                       129.52±13.95                                   156.82±12.70^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"}^        120.32±17.32^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"},[b](#tfn2-etm-0-0-8626){ref-type="table-fn"}^   167.24±14.86^[a-c](#tfn1-etm-0-0-8626 tfn2-etm-0-0-8626 tfn3-etm-0-0-8626){ref-type="table-fn"}^              0.001
  Laboratory data                                                                                                                                                                                                                                                                                                                                                                  
       Neutrophil count, x10^9^/l        6.03±2.68                                      6.21±3.42                                                         6.44±2.88^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"}^                                                   7.43±3.75^[a-c](#tfn1-etm-0-0-8626 tfn2-etm-0-0-8626 tfn3-etm-0-0-8626){ref-type="table-fn"}^                 0.004
       Lymphocyte count, x10^9^/l        2.84±0.64                                      2.81±0.77                                                         1.59±0.30^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"},[b](#tfn2-etm-0-0-8626){ref-type="table-fn"}^      1.57±0.37^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"},[b](#tfn2-etm-0-0-8626){ref-type="table-fn"}^          \<0.001
       NLR                               2.25±1.20                                      2.44±1.70                                                         4.24±2.10^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"},[b](#tfn2-etm-0-0-8626){ref-type="table-fn"}^      5.09±3.05^[a-c](#tfn1-etm-0-0-8626 tfn2-etm-0-0-8626 tfn3-etm-0-0-8626){ref-type="table-fn"}^                 \<0.001
       MPV, fl                           10.45±0.97                                     10.85±0.73^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"}^          11.02±0.93^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"}^                                                  11.00±1.10^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"}^                                                      \<0.001
       MPVLR                             3.83±0.81                                      4.08±0.90                                                         7.21±1.66^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"},[b](#tfn2-etm-0-0-8626){ref-type="table-fn"}^      7.83±2.95^[a-c](#tfn1-etm-0-0-8626 tfn2-etm-0-0-8626 tfn3-etm-0-0-8626){ref-type="table-fn"}^                 \<0.001
       Peak CK-MB, U/l                   146 (84-249)                                   86 (64-186)                                                       144 (66-233)                                                                                              162 (53-375)                                                                                                  0.113
       Peak cTnT, ng/ml                  3.64 (2.25-5.70)                               4.29 (2.31-5.89)^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"}^    4.20 (2.82-6.09)^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"}^                                            6.85 (2.72-8.99)^[a-c](#tfn1-etm-0-0-8626 tfn2-etm-0-0-8626 tfn3-etm-0-0-8626){ref-type="table-fn"}^          \<0.001
       NT-proBNP, pg/ml                  885 (494-2,499)                                1,366 (741-3,215)^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"}^   1,239 (764-2,519)^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"}^                                           3,610 (1,750-6,800)^[a-c](#tfn1-etm-0-0-8626 tfn2-etm-0-0-8626 tfn3-etm-0-0-8626){ref-type="table-fn"}^       \<0.001
       Glu, mmol/l                       7.32±3.93                                      7.73±3.54                                                         7.97±4.40                                                                                                 7.92±3.22                                                                                                     0.476
       hsCRP, mg/l                       2.60 (1.40-9.38)                               1.40 (0.87-3.20)^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"}^    1.72 (0.85-5.50)^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"}^                                            2.70 (1.64-5.45)^[b](#tfn2-etm-0-0-8626){ref-type="table-fn"},[c](#tfn3-etm-0-0-8626){ref-type="table-fn"}^   0.002
       LVEF                              59.52±9.24                                     59.46±10.81                                                       57.56±8.53^[a](#tfn1-etm-0-0-8626){ref-type="table-fn"},[b](#tfn2-etm-0-0-8626){ref-type="table-fn"}^     52.65±10.19^[a-c](#tfn1-etm-0-0-8626 tfn2-etm-0-0-8626 tfn3-etm-0-0-8626){ref-type="table-fn"}^               \<0.001
  Culprit vessel, n (%)                                                                                                                                                                                                                                                                                                                                                           0.327
       Right coronary artery             80 (44.20)                                     30 (32.97)                                                        38 (40.86)                                                                                                37 (37.37)                                                                                                     
       Left circumflex artery            23 (12.71)                                     10 (10.98)                                                        12 (12.90)                                                                                                13 (13.13)                                                                                                     
       Left anterior descending artery   78 (43.09)                                     49 (53.58)                                                        43 (46.24)                                                                                                47 (47.47)                                                                                                     
       Left main coronary artery         0 (0)                                          2 (2.20)                                                          0 (0)                                                                                                     2 (2.03)                                                                                                       
       Number of implanted stents, n     1.21±0.57                                      1.31±0.59                                                         1.17±0.50                                                                                                 1.22±0.56                                                                                                     0.942
  Postoperative medication, n (%)                                                                                                                                                                                                                                                                                                                                                  
       Clopidogrel                       167 (92.23)                                    86 (94.51)                                                        88 (94.62)                                                                                                92 (92.93)                                                                                                    0.848
       Aspirin                           173 (95.58)                                    85 (93.41)                                                        89 (95.70)                                                                                                96 (96.97)                                                                                                    0.709
       Statin                            153 (84.53)                                    79 (86.81)                                                        78 (83.87)                                                                                                90 (90.91)                                                                                                    0.436
       Beta-blocker                      144 (79.56)                                    68 (74.73)                                                        73 (78.49)                                                                                                80 (80.81)                                                                                                    0.753
       ACEI or ARB                       90 (49.72)                                     43 (47.25)                                                        49 (52.69)                                                                                                55 (55.56)                                                                                                    0.669
       Calcium channel blocker           40 (22.10)                                     18 (19.78)                                                        22 (23.68)                                                                                                30 (30.30)                                                                                                    0.332

MPVLR, mean platelet volume to lymphocyte ratio; GRACE, global registry of acute coronary events; NLR, neutrophil to lymphocyte ratio; MPV, mean platelet volume; CK-MB, creatine kinase isozyme; cTnT, cardia troponin T; NT-proBNP, n-terminal brain natriuretic peptide precursor; Glu, fasting blood sugar; hsCRP, high sensitivity c-reactive protein; LVEF, left ventricular ejection fraction; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin type II receptor blockers.

^a^P\<0.05 vs. low MPVLR + low GRACE.

^b^P\<0.05 vs. low MPVLR + high GRACE.

^c^P\<0.05 vs. high MPVLR + low GRACE.

###### 

Comparison of baseline clinical characteristics of patients in the MACE and MACE-free groups.

  Variable                               MACE group (n=54)     MACE-free group (n=410)   P-value
  -------------------------------------- --------------------- ------------------------- ---------
  Baseline characteristics                                                                
       Age, years                        71.19±11.29           58.11±10.69               \<0.001
       Male, n (%)                       32 (59.26)            236 (57.56)               0.812
       Current smokers, n (%)            34 (62.96)            206 (50.24)               0.079
       Hypertension, n (%)               44 (81.48)            286 (69.76)               0.074
       Diabetes mellitus, n (%)          28 (51.85)            128 (31.22)               0.003
       Dyslipidaemia, n (%)              19 (35.19)            103 (25.12)               0.114
       Prodromal angina, n (%)           11 (20.37)            144 (35.12)               0.031
       Killip class ≥II, n (%)           30 (55.56)            166 (40.49)               0.035
       GRACE score                       165.31±17.32          138.56±24.06              \<0.001
  Laboratory data                                                                         
       Neutrophil count, x10^9^/l        8.19±3.17             6.49±3.18                 \<0.001
       Lymphocyte count, x10^9^/l        1.70 (1.38-2.00)      2.30 (1.80-2.90)          \<0.001
       NLR                               4.61 (3.47-6.40)      2.44 (1.53-4.33)          \<0.001
       MPV, fl                           10.90 (10.60-11.80)   10.70 (10.10-11.40)       0.002
       MPVLR                             6.39 (5.64-8.10)      4.61 (3.66-6.00)          \<0.001
       Peak CK-MB, U/l                   166 (41-300)          137 (69-245)              0.914
       Peak cTnT, ng/ml                  7.15 (3.67-9.70)      4.09 (2.47-6.02)          \<0.001
       NT-proBNP, pg/ml                  3,800 (1,736-4,602)   1,209 (650-2,609)         \<0.001
       Glu, mmol/l                       8.35±3.72             7.59±3.83                 0.171
       hsCRP, mg/l                       3.25 (1.58-8.28)      2.25 (1.10-5.71)          0.041
       LVEF                              48.94±8.46            58.79±9.61                \<0.001
  Culprit vessel, n (%)                                                                   
       Right coronary artery             18 (33.33)            160 (39.02)               0.419
       Left circumflex artery            8 (14.81)             67 (16.34)                0.775
       Left anterior descending artery   27 (50.00)            180 (43.90)               0.397
       Left main coronary artery         1 (1.85)              3 (0.73)                  0.403
       Number of implanted stents, n     1.25±0.65             1.22±0.55                 0.770
  Postoperative medication, n (%)                                                         
       Clopidogrel                       50 (92.59)            383 (93.41)               0.820
       Aspirin                           51 (94.44)            392 (95.61)               0.699
       Statin                            46 (85.19)            354 (86.34)               0.817
       Beta-blocker                      42 (77.78)            323 (78.78)               0.866
       ACEI or ARB                       26 (48.15)            211 (51.46)               0.647
       Calcium channel blocker           12 (22.22)            98 (23.90)                0.785

MACE, major adverse cardiovascular events; MPVLR, mean platelet volume to lymphocyte ratio; GRACE, global registry of acute coronary events; NLR, neutrophil to lymphocyte ratio; MPV, mean platelet volume; CK-MB, creatine kinase isozyme; cTnT, cardia troponin T; NT-proBNP, n-terminal brain natriuretic peptide precursor; Glu, fasting blood sugar; hsCRP, high sensitivity c-reactive protein; LVEF, left ventricular ejection fraction; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin type II receptor blockers.

###### 

Comparison of adverse outcomes among the four groups based on the MPVLR and GRACE score cut-off.

  Variable                          Low MPVLR + low GRACE score (Group 1, n=181)   Low MPVLR + high GRACE score (Group 2, n=91)               High MPVLR + low GRACE score (Group 3, n=93)               High MPVLR + high GRACE score (Group 4, n=99)                                                    P-value
  --------------------------------- ---------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------------------------------------------------------ ---------
  Angiographic no-reflow, n (%)     8 (4.42)                                       13 (14.29)^[a](#tfn4-etm-0-0-8626){ref-type="table-fn"}^   12 (12.90)^[a](#tfn4-etm-0-0-8626){ref-type="table-fn"}^   26 (26.26)^[a-c](#tfn4-etm-0-0-8626 tfn5-etm-0-0-8626 tfn6-etm-0-0-8626){ref-type="table-fn"}^   \<0.001
  MACE during follow-up, n (%)      6 (3.30)                                       10 (11.00)^[a](#tfn4-etm-0-0-8626){ref-type="table-fn"}^   13 (13.98)^[a](#tfn4-etm-0-0-8626){ref-type="table-fn"}^   25 (25.25)^[a-c](#tfn4-etm-0-0-8626 tfn5-etm-0-0-8626 tfn6-etm-0-0-8626){ref-type="table-fn"}^   \<0.001
  Cardiac or all-cause death        2 (1.10)                                       3 (3.30)                                                   4 (4.29)                                                   13 (13.13)^[a-c](#tfn4-etm-0-0-8626 tfn5-etm-0-0-8626 tfn6-etm-0-0-8626){ref-type="table-fn"}^   \<0.001
  Malignant arrhythmia              1 (0.55)                                       2 (2.20)                                                   1 (1.08)                                                   3 (3.03)                                                                                         0.307
  Recurrent angina                  0 (0.00)                                       3 (3.30)                                                   2 (2.15)                                                   6 (6.07)^[a-c](#tfn4-etm-0-0-8626 tfn5-etm-0-0-8626 tfn6-etm-0-0-8626){ref-type="table-fn"}^     0.003
  Recurrent myocardial infarction   1 (0.55)                                       0 (0.00)                                                   2 (2.15)                                                   1 (1.01)                                                                                         0.424
  Acute heart failure               2 (1.10)                                       2 (2.20)                                                   3 (3.23)                                                   1 (1.01)                                                                                         0.552
  Stroke                            0 (0.00)                                       0 (0.00)                                                   1 (1.08)                                                   1 (1.01)                                                                                         0.366

MACE, major adverse cardiovascular events; MPVLR, mean platelet volume to lymphocyte ratio; GRACE, global registry of acute coronary events.

^a^P\<0.05 vs. low MPVLR + low GRACE.

^b^P\<0.05 vs. low MPVLR + high GRACE.

^c^P\<0.05 vs. high MPVLR + low GRACE.

###### 

Cox regression analysis of risk factors for MACE in patients during follow-up.

                            Multivariate analysis                                                                   
  ------------------------- ----------------------- --------- --------------------- --------- --------------------- ---------
  Age                       1.088 (1.062-1.234)     \<0.001   1.055 (1.025-1.131)   \<0.001   1.048 (1.017-1.113)   0.002
  Diabetes mellitus         1.453 (0.921-1.964)     0.236     \-                    \-        \-                    \-
  Prodromal angina          0.946 (0.795-0.991)     0.042     0.910 (0.839-0.963)   0.026     0.885 (0.816-0.947)   0.021
  Killip class ≥II          1.786 (1.036-2.886)     0.036     1.721 (1.324-2.320)   0.019     1.611 (1.266-1.897)   0.026
  NLR                       1.315 (1.144-1.545)     \<0.001   1.152 (1.089-1.418)   0.020     1.128 (1.102-1.407)   0.012
  hsCRP                     1.485 (1.122-1.676)     0.042     1.233 (1.076-1.538)   0.033     1.184 (1.076-1.510)   0.019
  NT-proBNP                 1.032 (1.001-1.095)     \<0.001   1.008 (1.000-1.039)   0.027     1.005 (1.002-1.027)   0.013
  Peak cTnT                 1.471 (1.086-1.787)     \<0.001   1.325 (0.987-1.880)   0.521     1.252 (0.932-1.780)   0.475
  LVEF                      0.928 (0.863-0.953)     \<0.001   0.911 (0.895-0.947)   \<0.001   0.903 (0.880-0.928)   \<0.001
  MPVLR \>5.38              2.987 (2.247-4.568)     \<0.001   1.668 (1.202-2.170)   \<0.001   \-                    \-
  GRACE \>145               3.102 (1.691-4.926)     \<0.001   1.706 (1.435-3.058)   \<0.001   \-                    \-
  Low MPVLR+ high GRACE     2.105 (1.358-6.281)     0.013     \-                    \-        1.625 (1.168-2.609)   0.007
  High MPVLR + low GRACE    2.558 (1.637-7.002)     0.022     \-                    \-        1.806 (1.392-2.809)   0.018
  High MPVLR + high GRACE   5.382 (3.745-8.753)     \<0.001   \-                    \-        2.455 (1.736-3.188)   \<0.001

MPVLR, mean platelet volume to lymphocyte ratio; GRACE, global registry of acute coronary events; NLR, neutrophil to lymphocyte ratio; hsCRP, high sensitivity c-reactive protein; cTnT, cardiac troponin T; NT-proBNP, n-terminal brain natriuretic peptide precursor; LVEF, left ventricular ejection fraction; HR, hazard ratio.
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